Welcome to our dedicated page for GLOBUS MEDICAL SEC filings (Ticker: GMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on GLOBUS MEDICAL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into GLOBUS MEDICAL's regulatory disclosures and financial reporting.
Globus Medical Inc. reported that executive Kelly G. Huller, EVP, General Counsel and Corporate Secretary, received a grant of stock options on January 21, 2026. The award covers 40,000 stock options to buy Class A common stock at an exercise price of $94.15 per share, with the options held directly.
According to the vesting terms, the options vest over four years, with 25% vesting on January 1, 2027, and the remaining options vesting in equal monthly installments of 1/48 each month thereafter. The options have an expiration date of January 21, 2036, giving the executive a long-term incentive tied to the company’s share performance.
Globus Medical Inc. senior vice president and CFO filed an amended insider trading report updating details of a prior stock option exercise and share sale. The amendment clarifies that on December 1, 2025, the officer exercised 4,896 stock options with an exercise price of $63.68 and then sold the underlying 4,896 shares of Class A common stock, rather than 5,000 options as previously reported.
The options relate to a grant made on January 27, 2022, which vests over four years, with one-fourth vesting on January 1, 2023 and the remainder vesting monthly over the following 36 months, and they expire on January 27, 2032. Following the corrected transaction, the officer beneficially owns 104 derivative securities (remaining options) directly.
Globus Medical Senior Vice President and CFO Kyle Kline reported exercising stock options and selling the underlying shares. On January 8, 2026, he exercised 3,594 stock options for Class A common stock at an exercise price of $51.87 per share, receiving 3,594 shares. That same day, he sold 3,594 Class A common shares at a price of $101.10 per share under transaction code "S." After these transactions, he reported 0 shares of Class A common stock directly owned and 3,906 stock options remaining. The sale was carried out under a Rule 10b5-1 trading plan dated August 25, 2025, and the options exercised were part of a grant from March 14, 2024 that vests over four years.
Globus Medical director reports preset stock sale
Globus Medical director Leslie V. Norwalk reported selling 2,000 shares of the company’s Class A common stock on January 8, 2026 at a price of $101.10 per share. After this transaction, Norwalk beneficially owned 10,419 Class A shares, all held directly. The filing notes that the sale was made under a Rule 10b5-1 trading plan that was put in place on September 12, 2025, indicating the trades were pre-arranged rather than decided at the time of sale.
GMED insider plans a new stock sale under Rule 144. A person identified in the filing plans to sell 3,594 shares of common stock through Raymond James & Associates on the NYSE, with an indicated aggregate market value of 363,167.00. These shares were acquired from the issuer on 01/08/2026 through a cashless option exercise on the same date. The filing notes that 133,839,166 shares of common stock were outstanding. Over the prior three months, Kyle Kline sold 18,542 common shares on 12/01/2025, generating gross proceeds of 1,667,846.00. The signer represents that they are not aware of undisclosed material adverse information about the issuer.
GMED insider plans a small stock sale under Rule 144. A holder, identified as Leslie Norwalk, has filed to sell up to 2,000 shares of GMED common stock on the NYSE through Raymond James & Associates, with an indicated aggregate market value of $202,000. GMED had 133,839,166 common shares outstanding at the time listed.
The shares to be sold come from 10,000 common shares acquired on 09/01/2023 through RSU vesting from the issuer. Over the prior three months, the same seller disposed of 4,000 common shares on 12/12/2025 for gross proceeds of $355,188.
Globus Medical, Inc. reported preliminary unaudited net sales results for the fourth quarter and full fiscal year ended December 31, 2025. At the same time, the company issued preliminary guidance for certain financial measures for the fiscal year ending December 31, 2026, giving investors an early view of expected performance for the coming year. These updates were shared through a press release dated January 7, 2026, which is furnished as an exhibit to this report.
Globus Medical Inc. director reports equity gift
A director of Globus Medical Inc. reported a transaction in the company’s Class A common stock dated 01/02/2025 with transaction code "G", indicating a gift. The filing shows 6,100 shares of Class A common stock were disposed of at a stated price of $0 as part of this gift transaction.
Following the reported transaction, the director beneficially owns 510,175 shares of Class A common stock directly. In addition, 165,967 shares are held indirectly through the Davidar Family Irrevocable Trust U/A 8/6/09, which is a trust for the benefit of the reporting person’s spouse and children, with the spouse serving as trustee.
Globus Medical Inc. director reported selling 4,000 shares of Class A common stock on 12/12/2025 at $88.85 per share in a transaction carried out under a Rule 10b5-1 trading plan dated September 12, 2025.
Following this planned sale, the director directly owns 12,419 shares of Globus Medical stock, as disclosed in the Form 4 filing.
GMED has a notice of proposed insider share sales under Rule 144. The filer plans to sell 4,000 shares of GMED common stock through Raymond James & Associates on the NYSE, with an aggregate market value of $355,000. The filing lists 133,839,166 shares of this class outstanding.
The seller acquired 10,000 common shares on 09/01/2023 through restricted stock unit (RSU) vesting from the issuer, and the planned sale represents part of that amount. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about GMED’s current or future operations.